Authors: Anne Rigg; Daniela Lee; Kerry Raynes; Narottam Thanvi; Apurna Jegannathen; Jayant S. Vaidya; Daniel Rea; H. M. Earl; Anthony Neal; Jennifer Marshall; Sarah Smith; Daniel Nelmes; Helen Innes; S O'Reilly; Daniel Epurescu; Peter Simmonds; Shrushma Loi; Anita Chhabra; Mariam Jafri; Nawaz Walji; Caroline Archer; Nicola Storey; Margaret Daly; David Miles; Mei-Lin Ah-See; Sundus Yahya; Rozenn Allerton; Jane Brown; Mark Harries; Simon Waters; Adrian Harnett; Richard Simcock; Susan Cleator; Betania Mahler Araujo; Ioannis Gounaris; Louise Hiller; Anne-Laure Vallier; Perric Crellin; Chee Goh; Trevor McGolick; Mark Churn; Muireann Kelleher; David J. Eaton; Karen McAdam; Chris Plummer; Carol MacGregor; Carlos Caldas; Robert Grieve; Fharat A. Raja; Donna L. Howe; Helen B Higgins; Helen Roe; Kathryn Wright; Mukesh Mukesh; Carolyn Bedi; Mojca Persic; Karen Tipples; Hafiz Algurafi; Aian Moss; Anne C Armstrong; Shiroma De Silva-Minor; Jacqueline Newby; Rakesh Mehra; A.S. Dhadda; Larry Hayward; Peter Ostler; Susan Lupton; Urmila Barthakur; Helena M. Earl; Eliot Sims; Janine Mansi; Chris Bradley; Maggie Wilcox; David Cameron; Janet A. Dunn; Charlotte Moss; O.S. Din; Natasha Mithal; Hartmut Kristeleit; Peter Hall; Elena Provenzano; D. Bloomfield; Catherine Reed; Anup Vinayan; Catherine Bale; Sue Down; Laura Pettit; Sanjay Raj; Christopher McCabe; Luke Hughes-Davies; Catherine Harper-Wynne; Lisa H Barraclough; Kim Benstead; Maher Hadaki; Andrew D. Goodman; Mohammad Butt; Rebecca Bowen; Andrew M Wardley; Andrew Eichholz; Helen Neville-Webbe; Wendy Taylor; Jean Abraham; Mohini Varughese; Nihal Shah; Pamela Woodings; Roshan Agarwal; Claire Hulme; A. Humphreys; Zafar Malik; Joanne Cliff

Venue: The Lancet

Type: Publication

Abstract: BACKGROUND: Adjuvant trastuzumab significantly improves outcomes for patients with HER2-positive early breast cancer. The standard treatment duration is 12 months but shorter treatment could provide similar efficacy while reducing toxicities and cost. We aimed to investigate whether 6-month adjuvant trastuzumab treatment is non-inferior to the standard 12-month treatment regarding disease-free survival. METHODS: This study is an open-label, randomised phase 3 non-inferiority trial. Patients were recruited from 152 centres in the UK. We randomly... (read more)

DOI: 10.17863/cam.37618